Confounding factors contribute to unexpected results of trial of renal denervation

New analysis shows how confounding factors may have had significant impact on SYMPLICITY HTN-3 trial results for blood pressure-lowering procedure

2014-12-08

(Press-News.org) A new analysis of an important trial of the blood pressure-lowering procedure, renal denervation, shows that the main results may have been affected by a number of confounding factors that partially explain the unexpected blood pressure responses in patients.

The analysis, published in the European Heart Journal [1], identified factors in the SYMPLICITY HTN-3 trial, such as variations in the way the procedure was performed and changes in patients' medications and drug adherence, which may have had a significant impact on the results.

Results of the SYMPLICITY HTN-3 trial [2] sent shock waves through the cardiology community when they appeared to show that there was no significant difference in patient outcome between renal denervation and a sham procedure among patients with drug resistant hypertension. As a result, renal denervation procedures came to a halt.

Professor Thomas Lüscher, editor-in-chief of the European Heart Journal, said: "SYMPLICITY HTN-3 resulted in referrals for the procedure drying up completely, making further trials almost impossible. However, in the analysis published in the European Heart Journal, David Kandzari and colleagues shed light for the first time on the interpretation of the results and suggest that in many patients the number of renal denervations was probably insufficient to achieve the proper degree of reduction in blood pressure that previous research had suggested was possible."

Renal denervation is a minimally invasive procedure by which a catheter is inserted via an artery in the groin to reach the renal arteries (the arteries that supply the kidneys with blood). The catheter delivers a series of two-minute blasts of radiofrequency energy along each renal artery to disrupt the nerves. This is called radiofrequency ablation and by deactivating the renal nerves and, therefore, reducing sympathetic nerve drive, cardiologists aim to achieve a significant and sustainable reduction in blood pressure.

Prof Lüscher, who has co-authored an editorial [3] to accompany Prof Kandzari's paper, said: "Professor Kandzari's analysis shows there were significant variations in the way that patients in SYMPLICITY HTN-3 were ablated. His sub-analysis now shows, for the first time, that if patients received 12 or more ablations in the trial, they experienced the same blood pressure reduction as in the earlier, SYMPLICITY HTN-2 trial and as reported by a large number of registries."

The analysis by Prof Kandzari, director of interventional cardiology and chief scientific officer at Piedmont Heart Institute, Atlanta, USA, and his colleagues showed there was a link between the number of ablations and the subsequent reduction in blood pressure, because consistent and greater reductions in systolic blood pressure and heart rate were identified with a higher number of renal artery ablations. The sub-analysis also looked at variability in the way the renal denervation procedure was performed, and demonstrated greater decreases in systolic blood pressure depending upon ablation patterns.

"For instance, patients who received between 11 and 14 or more renal ablations had reductions in systolic blood pressure (as measured during visits to the clinic) of 5-14 mmHg more than similar patients having the sham procedure. However, a greater effect of renal denervation compared with the sham procedure was not seen in patients who had ten or fewer ablations. Overall, the number of ablation attempts ranged from one to 26, with most patients receiving at least eight ablations. Giving four ablations in a spiral (helical) pattern in both renal arteries was also associated with greater reductions in systolic blood pressure, but this was only done in 19 patients," said Prof Kandzari.

"These findings lead us to the hypothesis that the variability in how the procedure was performed may have contributed to the difference in efficacy seen in SYMPLICITY HTN-3 versus other SYMPLICITY studies. This opens the field for new trials confirming that more ablations delivered in a spiral pattern are able to provide an effective denervation. With this new information, renal nerve ablation may recover and new trials can be performed, which may provide the evidence needed to back up anecdotal and registry evidence that the procedure can save patients lives by successfully lowering of blood pressure in hypertensive patients at risk of heart attacks and strokes."

Other confounding factors were the changes to medications and patient adherence to their drugs. The protocol for the SYMPLICITY HTN-3 trial specified that patients should be maintained on several anti-hypertensive medications at the highest possible doses, without any changes unless clinically necessary, from the time of enrolment to the end of the six-month follow-up period. During this time, approximately 40 percent of patients required medication changes; nearly 70% of those drug changes were due to patients experiencing adverse events or side-effects related to the maximally-tolerated dosage of their hypertension medications.

"The extent of these medication changes was not expected given the trial design, and it's important that we further evaluate if these frequent medication changes could have contributed to efficacy outcomes seen in SYMPLICITY HTN-3," said Prof Kandzari. "This analysis also suggests that changes in patient adherence to complex drug therapy could be another factor to partly explain the large blood pressure drop in patients who got the sham procedure. It was noted, for example, that a higher proportion of African-Americans were prescribed vasodilator therapy, and marked reductions in blood pressure were seen in the sham group of African-Americans in the trial."

He concluded: "Though further research is necessary to ultimately determine the full clinical potential of renal denervation, these analyses are important to guide us in the right direction for future trials. With this new information, new trials can be performed that may provide the evidence needed to back up anecdotal and registry evidence that the procedure can potentially improve patient outcomes by successfully lowering of blood pressure in hypertensive patients at risk of heart attacks and strokes."

INFORMATION:

Notes: [1] "Predictors of blood pressure response in the SYMPLICITY HTN-3 trial", by David E. Kandzari et al. European Heart Journal. doi:10.1093/eurheartj/ehu441. Published online: http://eurheartj.oxfordjournals.org/content/early/2014/11/13/eurheartj.ehu441 [2] "A controlled trial of renal denervation for resistant hypertension", by Deepak L. Bhatt et al. New England Journal of Medicine 2014; 370:1393-1401; April 10, 2014; doi: 10.1056/NEJMoa1402670 [3] "Renal denervation: simply trapped by complexity?", by Felix Mahfoud and Thomas Felix Lüscher. European Heart Journal. doi:10.1093/eurheartj/ehu450. Published online: http://eurheartj.oxfordjournals.org/content/early/2014/11/13/eurheartj.ehu450

ELSE PRESS RELEASES FROM THIS DATE:

X-ray laser acts as tool to track life's chemistry

2014-12-08

An international research team that includes researchers from Lawrence Livermore National Laboratory has captured the highest-resolution protein snapshots ever taken with an X-ray laser, revealing how a key protein in a photosynthetic bacterium changes shape when hit by light. Human biology is a massive collection of chemical reactions and all involve proteins, known as the molecules of life. Scientists have been moving steadily toward their ultimate goal of following these life-essential reactions step by step in real time, at the scale of atoms and electrons. "These ...

Novel strategies direct immune system to attack recurrent, hard-to-treat blood cancers

2014-12-08

(SAN FRANCISCO, December 6, 2014) - Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. Therapies designed to target the immune system and ignite the body's own disease-fighting mechanisms have become an increasingly promising field of study, particularly in blood cancers. While the immune system can easily recognize viruses ...

New technique allows low-cost creation of 3-D nanostructures

2014-12-08

Researchers from North Carolina State University have developed a new lithography technique that uses nanoscale spheres to create three-dimensional (3-D) structures with biomedical, electronic and photonic applications. The new technique is significantly less expensive than conventional methods and does not rely on stacking two-dimensional (2-D) patterns to create 3-D structures. "Our approach reduces the cost of nanolithography to the point where it could be done in your garage," says Dr. Chih-Hao Chang, an assistant professor of mechanical and aerospace engineering ...

Cell division induces tissue ordering

2014-12-08

Nature's ingenious systems: A layer of cells called endothelial cells lines the interior of blood vessels. When blood flows through the vessels, such cells only divide to replace dead cells. However, if there is a blood clot preventing blood from flowing across the endothelial cells, they begin to divide more actively. New research from the Niels Bohr Institute demonstrates that cell division is very ordered. The new cells move away from each other and create a dynamic movement with eddies in a large area. This presumably helps to widen the vessel around the blockage. The ...

Study finds early warning signals of abrupt climate change

2014-12-08

A new study by researchers at the University of Exeter has found early warning signals of a reorganisation of the Atlantic oceans' circulation which could have a profound impact on the global climate system. The research, published today in the journal Nature Communications, used a simulation from a highly complex model to analyse the Atlantic Meridional Overturning Circulation (AMOC), an important component of the Earth's climate system. It showed that early warning signals are present up to 250 years before it collapses, suggesting that scientists could monitor ...

Scientists pinpoint a new line of defence used by cancer cells

2014-12-08

Cancer Research UK scientists have discovered a new line of defence used by cancer cells to evade cell death, according to research published in Nature Communications* today (Monday). The team identified a critical pathway of molecular signals which throw a lifeline to cancer cells, enabling them to survive even though they contain vast DNA errors which would usually trigger cell death. The PKCƐ signal pathway**, which is used by cancer cells but rarely by normal cells, could be important in targeting some cancer cells as they rely on this pathway to survive. The ...

Unusual electronic state found in new class of unconventional superconductors

2014-12-08

UPTON, NY-A team of scientists from the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, Columbia Engineering, Columbia Physics and Kyoto University has discovered an unusual form of electronic order in a new family of unconventional superconductors. The finding, described in the journal Nature Communications, establishes an unexpected connection between this new group of titanium-oxypnictide superconductors and the more familiar cuprates and iron-pnictides, providing scientists with a whole new family of materials from which they can gain deeper insights ...

Most elderly women with early stage breast cancer receive a treatment that may not be as effective

2014-12-08

A new analysis has found that while clinical trial data support omitting radiation treatments in elderly women with early stage breast cancer, nearly two-thirds of these women continue to receive it. The findings are published early online in Cancer, a peer-reviewed journal of the American Cancer Society. Results published in 2004 from a large, randomized clinical trial showed that adding radiation therapy to surgery plus tamoxifen does not reduce 5-year recurrence rates or prolong survival in elderly women with early stage tumors. Despite the findings, many doctors still ...

Older breast cancer patients still get radiation despite limited benefit

2014-12-08

DURHAM, N.C. - Women over the age of 70 who have certain early-stage breast cancers overwhelmingly receive radiation therapy despite published evidence that the treatment has limited benefit, researchers at Duke Medicine report. The study suggests that doctors and patients may find it difficult to withhold treatment previously considered standard of care, even in the setting of high quality data demonstrating that the advantages are small. "The onus is on physicians to critically analyze data to shape our treatment recommendations for patients, weighing the potential ...

Scientists reveal parchment's hidden stories

2014-12-08

Dublin, IRELAND Monday December 8th, 2014 - Millions of documents stored in archives could provide scientists with the key to tracing agricultural development across the centuries, according to new research completed at Trinity College Dublin and the University of York. Amazingly, thanks to increasingly progressive genetic sequencing techniques, the all-important historical tales these documents tell are no longer confined to their texts; now, vital information also comes from the DNA of the parchment on which they are written. Researchers used these state-of-the-art ...